Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer.
Colon cancer
Esophageal cancer
Fusobacterium nucleatum
Gastrointestinal cancer
Microbiome
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
02
07
2018
accepted:
12
09
2018
pubmed:
24
9
2018
medline:
18
12
2019
entrez:
24
9
2018
Statut:
ppublish
Résumé
Microbiome research is a rapidly advancing field in human cancers. Fusobacterium nucleatum is an oral bacterium, indigenous to the human oral cavity, that plays a role in periodontal disease. Recent studies have found that F. nucleatum can promote gastrointestinal tumor progression and affect the prognosis of the disease. In addition, F. nucleatum may contribute to the chemo-resistance of gastrointestinal cancers. This review summarizes recent progress in the pathogenesis of F. nucleatum and its impact on gastrointestinal cancer.
Identifiants
pubmed: 30244399
doi: 10.1007/s00535-018-1512-9
pii: 10.1007/s00535-018-1512-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-41Subventions
Organisme : Grant-in-Aid for Scientific Research
ID : 17H04273
Organisme : Grant-in-Aid for Scientific Research
ID : 17K19702
Organisme : Grant-in-Aid for Scientific Research
ID : 17KK0195
Références
Arthur JC, Gharaibeh RZ, Muhlbauer M, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun. 2014;5:4724.
doi: 10.1038/ncomms5724
pubmed: 25182170
pmcid: 4155410
Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13:800–12.
doi: 10.1038/nrc3610
pubmed: 24132111
pmcid: 24132111
Abreu MT, Peek RM. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014;146:1534–46.
doi: 10.1053/j.gastro.2014.01.001
pubmed: 24406471
pmcid: 3995897
Al-Haddad S, El-Zimaity H, Hafezi-Bakhtiari S, et al. Infection and esophageal cancer. Ann N Y Acad Sci. 2014;1325:187–96.
doi: 10.1111/nyas.12530
pubmed: 25266025
Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12:661–72.
doi: 10.1038/nrmicro3344
pubmed: 25198138
pmcid: 25198138
Ley RE, Turnbaugh PJ, Klein S, et al. Human gut microbes associated with obesity. Nature. 2006;444:1022–3.
doi: 10.1038/4441022a
Ohkusa T, Okayasu I, Ogihara T, et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2003;52:79–83.
doi: 10.1136/gut.52.1.79
pubmed: 12477765
pmcid: 1773498
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.
doi: 10.1038/nature05485
Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12:16.
doi: 10.1186/1471-230X-12-16
pubmed: 22340817
pmcid: 3305584
Garrett WS. Cancer and the microbiota. Science. 2015;348:80–6.
doi: 10.1126/science.aaa4972
pubmed: 25838377
pmcid: 25838377
Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med. 2016;22:458–78.
doi: 10.1016/j.molmed.2016.04.003
pubmed: 27178527
pmcid: 4885777
Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science. 2016;352:535–8.
doi: 10.1126/science.aad9382
pubmed: 27126035
pmcid: 27126035
Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65:1906–15.
doi: 10.1136/gutjnl-2016-312297
pubmed: 27531828
Bashir A, Miskeen AY, Hazari YM, et al. Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut. Tumour Biol. 2016;37:2805–10.
doi: 10.1007/s13277-015-4724-0
pubmed: 26718210
Han YW. Fusobacterium nucleatum: a commensal-turned pathogen. Curr Opin Microbiol. 2015;23:141–7.
doi: 10.1016/j.mib.2014.11.013
pubmed: 25576662
Citron DM. Update on the taxonomy and clinical aspects of the genus fusobacterium. Clin Infect Dis. 2002;35:S22–7.
doi: 10.1086/341916
pubmed: 12173104
Signat B, Roques C, Poulet P, et al. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol. 2011;13:25–36.
pubmed: 21220789
Dzink JL, Sheenan MT, Socransky SS. Proposal of three subspecies of Fusobacterium nucleatum Knorr 1922: Fusobacterium nucleatum subsp. nucleatum subsp. nov., comb. nov.; Fusobacterium nucleatum subsp. polymorphum subsp. nov., nom. rev., comb. nov.; and Fusobacterium nucleatum subsp. vincentii subsp. nov., nom. rev., comb. nov. Int J Syst Bacteriol. 1990;40:74–8.
doi: 10.1099/00207713-40-1-74
pubmed: 2223601
Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.
doi: 10.1101/gr.126516.111
pubmed: 22009989
pmcid: 22009989
Kaplan CW, Lux R, Haake SK, et al. The Fusobacterium nucleatum outer membrane protein RadD is an arginine-inhibitable adhesin required for inter-species adherence and the structured architecture of multispecies biofilm. Mol Microbiol. 2009;71:35–47.
doi: 10.1111/j.1365-2958.2008.06503.x
pubmed: 19007407
Bachrach G, Ianculovici C, Naor R, et al. Fluorescence based measurements of Fusobacterium nucleatum coaggregation and of fusobacterial attachment to mammalian cells. FEMS Microbiol Lett. 2005;248:235–40.
doi: 10.1016/j.femsle.2005.05.055
pubmed: 15993010
Fardini Y, Wang X, Temoin S, et al. Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity. Mol Microbiol. 2011;82:1468–80.
doi: 10.1111/j.1365-2958.2011.07905.x
pubmed: 22040113
pmcid: 3237733
Han YW, Ikegami A, Rajanna C, et al. Identification and characterization of a novel adhesin unique to oral fusobacteria. J Bacteriol. 2005;187:5330–40.
doi: 10.1128/JB.187.15.5330-5340.2005
pubmed: 16030227
pmcid: 16030227
Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.
doi: 10.3322/caac.21395
pubmed: 28248415
pmcid: 28248415
Dienstmann R, Vermeulen L, Guinney J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79–92.
doi: 10.1038/nrc.2016.126
pubmed: 28050011
Burgess DJ. Gene expression: colorectal cancer classifications. Nat Rev Cancer. 2013;13:380–1.
doi: 10.1038/nrc3528
pubmed: 23640209
Flemer B, Warren RD, Barrett MP, et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 2018;67:1454–63.
doi: 10.1136/gutjnl-2017-314814
pubmed: 28988196
Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292–8.
doi: 10.1101/gr.126573.111
pubmed: 3266036
pmcid: 3266036
Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65:1973–80.
doi: 10.1136/gutjnl-2015-310101
pubmed: 26311717
Mima K, Cao Y, Chan AT, et al. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol. 2016;7:e200.
doi: 10.1038/ctg.2016.53
pubmed: 27811909
pmcid: 5543402
Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33:1381–90.
doi: 10.1007/s10096-014-2081-3
pubmed: 24599709
Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018;53:517–24.
doi: 10.1007/s00535-017-1382-6
pubmed: 28823057
Eklof V, Lofgren-Burstrom A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer. 2017;141:2528–36.
doi: 10.1002/ijc.31011
pubmed: 28833079
pmcid: 5697688
Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2017;66:1441–8.
doi: 10.1136/gutjnl-2016-312766
pubmed: 27797940
Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. 2017;23:2061–70.
doi: 10.1158/1078-0432.CCR-16-1599
pubmed: 27697996
Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015;137:1258–68.
doi: 10.1002/ijc.29488
pubmed: 25703934
Nosho K, Sukawa Y, Adachi Y, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol. 2016;22:557–66.
doi: 10.3748/wjg.v22.i2.557
pubmed: 26811607
pmcid: 4716059
Park HE, Kim JH, Cho NY, et al. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 2017;471:329–36.
doi: 10.1007/s00428-017-2171-6
pubmed: 28597080
Tahara T, Yamamoto E, Suzuki H, et al. Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Can Res. 2014;74:1311–8.
doi: 10.1158/0008-5472.CAN-13-1865
Lee DW, Han SW, Kang JK, et al. Association Between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018;25(11):3389–95.
doi: 10.1245/s10434-018-6681-5
pubmed: 30062471
Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195–206.
doi: 10.1016/j.chom.2013.07.012
pubmed: 23954158
pmcid: 23954158
Abed J, Emgard JE, Zamir G, et al. Fap2 Mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20:215–25.
doi: 10.1016/j.chom.2016.07.006
pubmed: 27512904
pmcid: 5465824
Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappaB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152:851–66.
doi: 10.1053/j.gastro.2016.11.018
pubmed: 27876571
Chen YY, Peng Y, Yu JH, et al. Invasive Fusobacterium nucleatum activates beta-catenin signaling in colorectal cancer via a TLR4/P-PAK1 cascade. Oncotarget. 2017;8:31802–14.
pubmed: 28423670
pmcid: 5458249
Yu YN, Yu TC, Zhao HZ, et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget. 2015;6:32013–26.
pubmed: 26397137
pmcid: 4741656
Kumar A, Thotakura PL, Tiwary BK, et al. Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions. BMC Microbiol. 2016;16:84.
doi: 10.1186/s12866-016-0700-0
pubmed: 27176600
pmcid: 4866016
Tang B, Wang K, Jia YP, et al. Fusobacterium nucleatum-induced impairment of autophagic flux enhances the expression of proinflammatory cytokines via ROS in Caco-2 cells. PLoS One. 2016;11:e0165701.
doi: 10.1371/journal.pone.0165701
pubmed: 27828984
pmcid: 5102440
Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42:344–55.
doi: 10.1016/j.immuni.2015.01.010
pubmed: 25680274
pmcid: 4361732
Saito T, Nishikawa H, Wada H, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22:679–84.
doi: 10.1038/nm.4086
pubmed: 27111280
Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T Cells in colorectal carcinoma. JAMA Oncol. 2015;1:653–61.
doi: 10.1001/jamaoncol.2015.1377
pubmed: 26181352
pmcid: 4537376
Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–15.
doi: 10.1016/j.chom.2013.07.007
pubmed: 23954159
pmcid: 23954159
Ye X, Wang R, Bhattacharya R, et al. Fusobacterium Nucleatum subspecies Animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors. Cancer Prev Res (Phila). 2017;10:398–409.
doi: 10.1158/1940-6207.CAPR-16-0178
pubmed: 28483840
Peters BA, Wu J, Pei Z, et al. Oral microbiome composition reflects prospective risk for esophageal cancers. Cancer Res. 2017;77:6777–87.
doi: 10.1158/0008-5472.CAN-17-1296
pubmed: 29196415
pmcid: 5726431
Yamamura K, Baba Y, Nakagawa S, et al. Human microbiome Fusobacterium Nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22:5574–81.
doi: 10.1158/1078-0432.CCR-16-1786
pubmed: 27769987
Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case–control study. Gut. 2018;67:120–7.
doi: 10.1136/gutjnl-2016-312580
pubmed: 27742762
Mitsuhashi K, Nosho K, Sukawa Y, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget. 2015;6:7209–20.
pubmed: 25797243
pmcid: 4466679
Yamamura K, Baba Y, Miyake K, et al. Fusobacterium nucleatum in gastroenterological cancer: evaluation of measurement methods using quantitative polymerase chain reaction and a literature review. Oncol Lett. 2017;14:6373–8.
pubmed: 29151903
pmcid: 5678348
Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358:1443–8.
doi: 10.1126/science.aal5240
pubmed: 29170280
pmcid: 5823247
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
doi: 10.3322/caac.20107
pubmed: 21296855
pmcid: 21296855
Castano-Rodriguez N, Goh KL, Fock KM, et al. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep. 2017;7:15957.
doi: 10.1038/s41598-017-16289-2
pubmed: 29162924
pmcid: 5698432
Hsieh YY, Tung SY, Pan HY, et al. Increased abundance of clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci Rep. 2018;8:158.
doi: 10.1038/s41598-017-18596-0
pubmed: 29317709
pmcid: 5760541
Wei ZL, Cao SG, Liu SL, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016;7:46158–72.
pubmed: 27323816
pmcid: 5216788
Yan X, Liu L, Li H, et al. Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. Onco Targets Ther. 2017;10:5031–46.
doi: 10.2147/OTT.S145949
pubmed: 29081665
pmcid: 5652912
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(548–563):e516.
Mehta RS, Nishihara R, Cao Y, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by Fusobacterium nucleatum in tumor tissue. JAMA Oncol. 2017;3:921–7.
doi: 10.1001/jamaoncol.2016.6374
pubmed: 28125762
pmcid: 5502000
Pollock J, Glendinning L, Wisedchanwet T, et al. The madness of microbiome: attempting to find consensus “best practice” for 16S microbiome studies. Appl Environ Microbiol. 2018;84(7). pii: e02627–17. https://doi.org/10.1128/AEM.02627-17 .
Liu L, Tabung FK, Zhang X, et al. Diets that promote colon inflammation associate with risk of colorectal carcinomas that contain Fusobacterium nucleatum. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.04.030 .
doi: 10.1016/j.cgh.2018.04.030
pubmed: 30529732
pmcid: 6162842
Chen T, Li Q, Zhang X, et al. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Hum Pathol. 2018;79:93–101.
doi: 10.1016/j.humpath.2018.05.008
pubmed: 29792893
Li YY, Ge QX, Cao J, et al. Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients. World J Gastroenterol. 2016;22:3227–33.
doi: 10.3748/wjg.v22.i11.3227
pubmed: 27004000
pmcid: 4789998
Wang HF, Li LF, Guo SH, et al. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep. 2016;6:33440.
doi: 10.1038/srep33440
pubmed: 27678333
pmcid: 5039407
Wu N, Yang X, Zhang R, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013;66:462–70.
doi: 10.1007/s00248-013-0245-9
pubmed: 23733170
Suehiro Y, Sakai K, Nishioka M, et al. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population. Ann Clin Biochem. 2017;54:86–91.
doi: 10.1177/0004563216643970
pubmed: 27126270
Mira-Pascual L, Cabrera-Rubio R, Ocon S, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J Gastroenterol. 2015;50:167–79.
doi: 10.1007/s00535-014-0963-x
pubmed: 24811328
Amitay EL, Werner S, Vital M, et al. Fusobacterium and colorectal cancer: causal factor or passenger? Results from a large colorectal cancer screening study. Carcinogenesis. 2017;38:781–8.
doi: 10.1093/carcin/bgx053
pubmed: 28582482
Guo SH, Wang HF, Nian ZG, et al. Immunization with alkyl hydroperoxide reductase subunit C reduces Fusobacterium nucleatum load in the intestinal tract. Sci Rep. 2017;7:10566.
doi: 10.1038/s41598-017-11127-x
pubmed: 28874771
pmcid: 5585165
Zanzoni A, Spinelli L, Braham S, et al. Perturbed human sub-networks by Fusobacterium nucleatum candidate virulence proteins. Microbiome. 2017;5:89.
doi: 10.1186/s40168-017-0307-1
pubmed: 28793925
pmcid: 5551000
Dix A, Vlaic S, Guthke R, et al. Use of systems biology to decipher host-pathogen interaction networks and predict biomarkers. Clin Microbiol Infect. 2016;22:600–6.
doi: 10.1016/j.cmi.2016.04.014
pubmed: 27113568